⚕ GalenOps field
←

SITE013-0426

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-08-18

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-10 (study day 199); relationship: Y

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-24 (study day 213); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-09 (study day 229); relationship: N

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-06-12 (study day 293); relationship: N

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-07-05 (study day 316); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-07-25 (study day 336); relationship: not assessed

Data queries

No data queries.